About: Anifrolumab

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus (SLE). It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β. Anifrolumab was approved for medical use in the United States in July 2021, and in the European Union in February 2022.

Property	Value
dbo:abstract	Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus (SLE). It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β. Anifrolumab was approved for medical use in the United States in July 2021, and in the European Union in February 2022. (en) アニフロルマブ（Anifrolumab）は、全身性エリテマトーデス（SLE）の治療に用いられるモノクローナル抗体である。に結合し、インターフェロン-α、インターフェロン-β等のI型インターフェロンの活性を阻害する[要出典医学]。 (ja)
dbo:alternativeName	Saphnelo (en)
dbo:casNumber	1326232-46-5
dbo:class	dbr:Type_I_interferon_receptor_antagonist
dbo:drugbank	DB11976
dbo:fdaUniiCode	38RL9AE51Q
dbo:kegg	D11082
dbo:wikiPageExternalLink	https://druginfo.nlm.nih.gov/drugportal/name/anifrolumab
dbo:wikiPageID	39886813 (xsd:integer)
dbo:wikiPageLength	11777 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1117135224 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Interferon-alpha/beta_receptor dbr:MedImmune dbr:Monoclonal_antibody dbr:Shingles dbr:Sifalimumab dbr:Committee_for_Medicinal_Products_for_Human_Use dbc:Cutaneous_lupus_erythematosus dbr:European_Medicines_Agency dbc:AstraZeneca_brands dbr:AstraZeneca dbc:Monoclonal_antibodies dbr:Systemic_lupus_erythematosus dbr:Placebo dbr:Interferon_type_I dbr:Intravenous dbr:Type_I_interferon_receptor_antagonist
dbp:atcPrefix	L04 (en)
dbp:atcSuffix	AA51 (en)
dbp:c	6444 (xsd:integer)
dbp:casNumber	1326232 (xsd:integer)
dbp:chemspiderid	none (en)
dbp:class	dbr:Type_I_interferon_receptor_antagonist
dbp:dailymedid	Anifrolumab (en)
dbp:drugbank	DB11976 (en)
dbp:h	9964 (xsd:integer)
dbp:kegg	D11082 (en)
dbp:legalAu	S4 (en)
dbp:legalCa	Rx-only (en)
dbp:legalEu	Rx-only (en)
dbp:legalUs	Rx-only (en)
dbp:mabType	mab (en)
dbp:n	1712 (xsd:integer)
dbp:o	2018 (xsd:integer)
dbp:pregnancyAu	C (en)
dbp:routesOfAdministration	dbr:Intravenous
dbp:s	44 (xsd:integer)
dbp:source	u (en)
dbp:synonyms	MEDI-546, anifrolumab-fnia (en)
dbp:target	dbr:Interferon-alpha/beta_receptor
dbp:tradename	Saphnelo (en)
dbp:type	mab (en)
dbp:unii	38 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Cite_journal dbt:Cite_web dbt:Drugbox dbt:Portal_bar dbt:Reflist dbt:Use_dmy_dates dbt:Fdacite dbt:Drugs.com dbt:Medcn dbt:Cytokine_receptor_modulators dbt:AstraZeneca dbt:ClinicalTrialsGov dbt:Monoclonals_for_immune_system dbt:Immunosuppressants
dct:subject	dbc:Cutaneous_lupus_erythematosus dbc:AstraZeneca_brands dbc:Monoclonal_antibodies
gold:hypernym	dbr:Antibody
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody yago:WikicatMonoclonalAntibodies yago:Abstraction100002137 yago:Antibody115027189 yago:Chemical114806838 yago:Compound114818238 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:MonoclonalAntibody115029781 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:Thing100002452 yago:Unit109465459
rdfs:comment	Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus (SLE). It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β. Anifrolumab was approved for medical use in the United States in July 2021, and in the European Union in February 2022. (en) アニフロルマブ（Anifrolumab）は、全身性エリテマトーデス（SLE）の治療に用いられるモノクローナル抗体である。に結合し、インターフェロン-α、インターフェロン-β等のI型インターフェロンの活性を阻害する[要出典医学]。 (ja)
rdfs:label	Anifrolumab (en) アニフロルマブ (ja)
owl:sameAs	freebase:Anifrolumab yago-res:Anifrolumab wikidata:Anifrolumab dbpedia-ja:Anifrolumab https://global.dbpedia.org/id/ZUxJ
prov:wasDerivedFrom	wikipedia-en:Anifrolumab?oldid=1117135224&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Anifrolumab
is dbo:wikiPageRedirects of	dbr:Anifrolumab-fnia dbr:Saphnelo dbr:C6444H9964N1712O2018S44
is dbo:wikiPageWikiLink of	dbr:Anifrolumab-fnia dbr:MedImmune dbr:Saphnelo dbr:Sifalimumab dbr:C6444H9964N1712O2018S44 dbr:ATC_code_L04 dbr:List_of_therapeutic_monoclonal_antibodies
is foaf:primaryTopic of	wikipedia-en:Anifrolumab